NCT00417430View on ClinicalTrials.gov

Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

ICI 182,780 (Faslodex)

Trial Locations (1)

64111

4330 Wornall suite 40, Kansas City

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

The Center for Rheumatic Disease, Allergy, & Immunology

OTHER

NCT00417430 - Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies | Biotech Hunter | Biotech Hunter